Huadong Medicine’s Patent Challenge Against Novo Nordisk’s Ozempic Heads to Hearing
February 23 will mark the oral hearing phase for the patent challenge case brought by...
NYSE: NVO
Novo Nordisk Posts Strong 2022 Results; GLP-1 Therapies Drive Growth
Denmark-based diabetes giant Novo Nordisk (NYSE: NVO) has reported financial results for the fourth quarter...
Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance
Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...
Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE
Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607,...
Novo Nordisk to Invest RMB 400M in Shanghai at CIIE
Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an...
Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip
Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...